BioCentury
ARTICLE | Politics, Policy & Law

CMS seeks public input as it launches NCD analysis for amyloid-targeting mAbs

Plus House Democrats request documents related to Aduhelm approval, pricing

July 13, 2021 12:49 AM UTC

CMS is seeking public input as it undergoes a National Coverage Determination (NCD) analysis to decide whether Medicare will establish a coverage policy for Biogen’s aducanumab and future amyloid-targeting mAbs to treat Alzheimer’s disease. An NCD could standardize coverage practices and set a benchmark for commercial insurers. 

The NCD analysis marks the beginning of a 30-day public comment period, and CMS will host two sessions this month to gather additional stakeholder input. The agency expects to post a proposed NCD within six months, followed by another 30-day public comment period and a final NCD within nine months. ...

BCIQ Company Profiles

Biogen Inc.

BCIQ Target Profiles

Beta amyloid